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Abstract
Background: There are profound individual differences in clinical outcomes between colorectal cancers (CRCs)
presenting with identical stage of disease. Molecular stratification, in conjunction with the traditional TNM staging,
is a promising way to predict patient outcomes. We investigated the interconnectivity between tumor stage and
tumor biology reflected by the Consensus Molecular Subtypes (CMSs) in CRC, and explored the possible value of
these insights in patients with stage II colon cancer.
Methods: We performed a retrospective analysis using clinical records and gene expression profiling in a meta-
cohort of 1040 CRC patients. The interconnectivity of tumor biology and disease stage was assessed by
investigating the association between CMSs and TNM classification. In order to validate the clinical applicability of
our findings we employed a meta-cohort of 197 stage II colon cancers.
Results: CMS4 was significantly more prevalent in advanced stages of disease (stage I 9.8% versus stage IV 38.5%,
p < 0.001). The observed differential gene expression between cancer stages is at least partly explained by the
biological differences as reflected by CMS subtypes. Gene signatures for stage III-IV and CMS4 were highly
correlated (r = 0.77, p < 0.001). CMS4 cancers showed an increased progression rate to more advanced stages (CMS4
compared to CMS2: 1.25, 95% CI: 1.08–1.46). Patients with a CMS4 cancer had worse survival in the high-risk stage II
tumors compared to the total stage II cohort (5-year DFS 41.7% versus 100.0%, p = 0.008).
Conclusions: Considerable interconnectivity between tumor biology and tumor stage in CRC exists. This implies
that the TNM stage, in addition to the stage of progression, might also reflect distinct biological disease entities.
These insights can potentially be utilized to optimize identification of high-risk stage II colon cancers.
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Background
Colorectal cancer (CRC) is the fourth most common
cancer worldwide and the second leading cause of
cancer mortality [1]. Clinical decision making in CRC
is mainly driven by clinical and traditional patho-
logical features including TNM staging. Although
these features hold considerable prognostic, and even
predictive value, there are profound individual differ-
ences in clinical outcome within a single tumor stage,
especially for stage II and III [2]. Also, there is com-
pelling evidence that not all cancers follow the linear-
progression model associating with the TNM-stages.
For example, in CRC the majority of lymphatic and
distant metastases arise from independent subclones,
and 40–63% of metachronous metastases develop in
patients without lymph node metastasis [3]. The con-
sensus molecular subtype (CMS) classification is a
widely studied transcriptome-based stratification sys-
tem for CRC defining four disease entities (CMS 1–4)
with distinct clinical, biological and molecular features
[4]. Hence, the CMS taxonomy could offer a frame-
work to elucidate whether TNM solely resembles dis-
ease progression or also biologically different entities
that preferentially present with a specific stage of dis-
ease at diagnosis. This study was conducted to inves-
tigate the interconnectivity between tumor stage and
tumor biology in CRC patients. Subsequently we
demonstrate the added value of this knowledge in pa-
tients with high-risk stage II colon cancer, a subgroup
in which accurate prognostication and selection for
adjuvant treatment is still an unmet need.
Methods
Patients and data aggregation
Patients for which information on staging and microsat-
ellite instability (MSI) status was available were selected
from the previously reported meta-cohort of Guinney
et al. [4], resulting in 1040 individual patients (accession
number GSE39582 [5] and TCGA). For validation of our
findings the chemotherapy naïve stage II CRC patients
of the MATCH Cohort [6] and AMC-AJCCII-90 Cohort
(accession number GSE33113) [7] were used. In the val-
idation cohort high-risk was defined as either T4 or in-
adequate lymph node assessment (< 10 nodes assessed).
The R2: Genomic Analysis and Visualization Platform
was used to extract the aggregated and normalized data
(http://r2.amc.nl).
CMS classification
Samples were classified into molecular subtypes using
the Random Forest (RF) method available in the R pack-
age of the CMS classifier (v1·0·0, https://www.synapse.
org/#!Synapse:syn4961785) [4].
Differential gene expression analysis
The limma package was used to identify differentially
expressed genes (DEG) between the different tumor
stages and CMS groups, using the ANOVA test for over-
all DEG and a limma-test for individual groups. P-values
were FDR corrected. For comparing the number of DEG
between the overall cohort and CMSs, a random set of
200 patients was sampled 1000 times to correct for the
effect of group size on the number of DEG.
Gene signatures
Gene signatures for advanced stage and CMS4 were
built using the top 100 DEG (with the lowest FDR cor-
rected p-value) between early (stage I-II) and advanced
stage (stage III-IV), and CMS1/2/3 and CMS 4. Gene
signature scores were built using the weighted matched
z-score of both the up- and downregulated genes of the
gene signatures.
Statistical analysis
The Chi-square test was used to assess associations be-
tween CMS classification and tumor stage. The Kaplan-
Meier method was used to estimate survival. Survival
curves were compared using the log-rank test. Disease-
free survival (DFS) times of > 60months were censored
at 60 months. We performed a multivariate analysis
using a Cox proportional-hazards model with CMS, gen-
der, age, tumor location, T-stage and MSI status as cov-
ariables. All statistical tests were 2-sided and considered
significant at a P-value lower than 0·05. All analyses
were performed using R version 3.6.1.
Results
Distinct TNM stages represent with different distributions
of molecular subtypes
We analyzed the association between CMS subtypes and
tumor stage in a meta-cohort comprising 1040 patients
(Table 1). An increase in prevalence of the poor-prognosis
mesenchymal subtype (CMS4) was detected in advanced
stages of disease (stage I 12 (9.8%), stage II 89 (22.9%), stage
III 94 (29.4%) and stage IV 45 (38.5%), p < 0.001) (Fig. 1 and
Additional file 1: Table S1). The same increase was observed
for the individual cohorts separately (Additional file 1: Table
S1 and Additional file 1: Fig. S1).
Tumor stage reflects tumor biology
We tested the hypothesis that tumor stage as defined by
TNM, does not only represent disease progression but
also reflects different biological entities. By investigating
the changes in the number of differentially expressed
genes, considerable gene expression differences between
TNM stages was revealed. These differences decreased
significantly when stratified for CMS2 and CMS4 repre-
senting the most common CMSs (Fig. 2a). This was
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confirmed when stratifying for all subtypes (CMS1–4)
(Additional file 1: Fig. S2). Furthermore, visualization of
the genes that displayed significant differences between
tumor stages (ANOVA p < 0.05, n = 2764) shows a clear
separation for the immune (CMS1), epithelial (CMS2/3)
and mesenchymal (CMS4) subtypes in both a t-SNE plot
and a gene expression heatmap (Fig. 2b and Additional
file 1: Fig. S3).
CMS4 correlates with more advanced stages and has a
higher progression rate
In order to specifically investigate the association be-
tween CMS4 and more advanced tumor stages, we built
two gene signatures to discriminate disseminated disease
(stage III-IV) from local disease (stage I-II), and to sep-
arate CMS4 cancers from CMS1/2/3 tumors (see
methods). Remarkably, the two scores were highly corre-
lated (r = 0.77, p < 0.001) (Fig. 2c), with only a few over-
lapping genes (13/200), suggesting that
overrepresentation of CMS4 cancers in stage III-IV can-
cers is responsible for gene expression differences be-
tween early and advanced malignancies.
Subsequently, we assessed the rate of progression from
early (stage I-II) to advanced (stage III-IV) tumor stage
for each of the subtypes by calculating the risk ratios.
This shows a markedly increased progression rate to-
wards more advanced stages for CMS4 cancers as com-
pared to CMS1 tumors (RR 1.64, 95% CI: 1.29–2.09),
CMS2 (RR 1.25, 95% CI: 1.08–1.46) and CMS3 (RR 1.57,
95% CI: 1.23–2.01) (Fig. 2d).
CMS4 holds prognostic value in high-risk stage II colon
cancer
In an effort to validate our findings and provide clinical
utility to the insight obtained, we evaluated chemother-
apy naive high-risk stage II colon cancers (Table 2).
Based on the association between CMSs and tumor
stage, we hypothesized that CMS4 cancers are over rep-
resented in high-risk stage II cancers. Indeed, in the
combined stage II cohorts, MATCH and GSE33113 (n =
197), CMS4 cancers were more prevalent in high-risk
stage II patients (21.7% vs 7.7%, p = 0.02 respectively)
(Table 2, Fig. 3a and Additional file 1: Table S2). DFS
for these patients confirmed the poor disease outcome
of CMS4 cancers (Fig. 3b). This effect was explained by
the poor outcome for patients with a CMS4 cancer in
the subgroup with high-risk tumors (5-year DFS 41.7%
versus 100.0%, p = 0.008) (Fig. 3c and Additional file 1:
Fig. S4). These findings were substantiated by a multi-
variate analysis, which showed a significant correlation
of CMS with DFS in the subgroup with high-risk tumors
but not in the total stage II cohort (Table 3 and Add-
itional file 1: Table S3). The extended GSE33113 cohort,
comprising of both stage II and stage III tumors, re-
vealed possible under-staging of high-risk stage II pa-
tients. With a rising number of assessed lymph nodes
the percentage of stage III colon cancers increased (Fig.
3d and Additional file 1: Table S4).
Discussion
At present we are moving towards a more personalized
medicine approach for the treatment of cancer. How-
ever, at this stage TNM staging is still the single most
important feature guiding treatment decisions for CRC.
The CMS classification is a promising classification sys-
tem for CRC, identifying four subtypes with distinguish-
ing biological features. CMS classification might be a
relevant addition to TNM staging in order to provide an
Fig. 1 Distribution of the molecular subtypes for each tumor stage.
Distribution in percentages (y-axis) of the CMS groups in the cohort
Table 1 Basic characteristics of the aggregated cohort (n =
1040)
Total GSE39582 TCGA
n = 1040 n = 511 n = 529
Gender Female 476 45.8% 227 44.4% 249 47.1%
Male 564 54.2% 284 55.6% 280 52.9%
Age Median (IQRa) 68 (59–77) 69 (59–76) 68 (59–77)
TNM I 133 12.8% 38 7.4% 95 18.0%
II 417 40.1% 216 42.3% 201 38.0%
III 355 34.1% 200 39.1% 155 29.3%
IV 135 13.0% 57 11.2% 78 14.7%
MSI MSS 887 85.3% 436 85.3% 451 85.3%
MSI 153 14.7% 75 14.7% 78 14.7%
CMS 1 153 14.7% 79 15.5% 74 14.0%
2 420 40.4% 214 41.9% 206 38.9%
3 133 12.8% 66 12.9% 67 12.7%
4 240 23.1% 112 21.9% 128 24.2%
Indeterminate 94 9.0% 40 7.8% 54 10.2%
aIQR Interquartile range
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Fig. 2 Gene expression analysis and risk ratio’s. a depicts the cumulative number of differentially expressed genes (y-axis) as a mean with 95% CI
(of 1000 times 200 random sampling) plotted against the p value used as cut-off to define differential expression (x-axis). b is a visualization of
the genes that display significant differences between tumor stages in the whole group (ANOVA p < 0.05, n = 2764) using a t-SNE algorithm with
clear separation of the immune (CMS1), mesenchymal (CMS4) and epithelial subtypes (CMS2/3). c displays the correlation between disseminated
disease (stage III-IV) (x-axis) and CMS4 (y-axis) signature scores (r = 0.77, p < 0.001). d shows risk ratio’s for progression to advanced stages of
disease (stage III-IV) and a 95% confidence interval comparing the different CMS subtypes
Table 2 Characteristics MATCH and GSE33113
Total MATCH cohort GSE33113
n = 197 n = 112 n = 85
Gender Female 101 51.3% 57 50.9% 44 51.8%
Male 96 48.7% 55 49.1% 41 48.2%
Age Median (IQR) 71.0 (63.0–77.0) 70.0 (63.0–76.0) 74.6 (61.9–80.2)
T 3 184 93.4% 107 95.5% 77 90,6%
4 13 6.6% 5 4.5% 8 9.4%
N Median (range) 14 (1–46) 14 (5–28) 12 (1–46)
N < 10 lymph nodes assesed 45 22.8% 14 12.5% 31 36.5%
≥ 10 lymph nodes assesed 142 72.1% 98 87.5% 44 51.8%
Missing 10 5.1% 0 0,0% 10 11.8%
MSI MSS 140 71.1% 79 70.5% 61 71.8%
MSI 52 26.4% 28 25.0% 24 28.2%
Missing 5 2.5% 5 4.5% 0 0.0%
CMS 1 49 24.9% 29 25.9% 20 23.5%
2 83 42.1% 52 46.4% 31 36.5%
3 19 9.6% 11 9.8% 8 9.4%
4 20 10.2% 5 4.5% 15 17,6%
Indeterminate 26 13.2% 15 13.4% 11 12.9%
IQR Interquartile range
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optimal treatment strategy for individual patients. Our
findings support the hypothesis that tumor stage as de-
fined by TNM, in addition to disease progression, re-
sembles different biological entities. This adds to the
argument that the CMS taxonomy is a potential
framework to further tailor the prognostication and
treatment of patients with CRC.
We have observed a difference in distribution for the
CMS within the different TNM stages with mainly a de-
crease in CMS1 and a profound increase of CMS4 pa-
tients with advancing stages of disease. This is in line
with the overall good prognosis of the CMS1, which are
mainly MSI tumors, and the poor prognosis of the mes-
enchymal CMS4 subtype [4]. This may suggest that the
poor prognosis for increased stages of disease is (in part)
explained by the aggressive tumor biology of CMS4,
given the poor disease outcome of CMS4 compared to
CMS1–3 cancers. The aggressive nature of the mesen-
chymal subtype was also demonstrated by a higher pro-
gression rate for CMS4 compared to the other subtypes
(Fig. 2d).
When stratified for CMSs, we observed a marked de-
crease in differentially expressed genes between the dif-
ferent tumor stages. Furthermore, a high correlation
between the two gene signature scores for stage III/IV
and CMS4 was demonstrated. This indicates that at least
part of the biological differences between tumor stages
Fig. 3 Lymph node assessment and disease free survival. a shows the distribution of CMS in stage II colon cancer (y-axis distribution in
percentages) stratified for high-risk. b and c display the disease free survival (x-axis in months) of a set of patients with stage II colon cancer of
the MATCH Cohort and GSE33113 (b), and the subset of patients with high-risk stage II colon cancer (T4 or < 10 assessed lymph nodes) (c). d
shows that the chance of finding a positive lymph node (y-axis) increases with an increasing number of assessed lymph nodes (x-axis), which
plateaus after 10 lymph nodes
Table 3 Multivariate analysis of relevant parameters and
disease-free survival for high-risk stage II patients
HR 95% CI limits
CMS 1 a
CMS 2 0.225 0.053–0.957







CMS Consensus molecular subtype, MSI Microsatellite instability
aNot estimable due to no events
bNot estimable due to no MSI patients
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are explained by the CMSs. Which in turn supports the
hypothesis that different tumor stages are largely driven
by tumor biology rather than disease progression.
Furthermore, we showed a possible and valuable clin-
ical implication of the molecular subtypes for the high-
risk stage II patients. Current guidelines recommend to
consider adjuvant chemotherapy for these patients [8],
which is based on literature showing (limited) prognostic
value but no predictive value for the high-risk variables
[9–13]. The overt difference in DFS for the CMS4 sub-
type in the subgroup of high-risk stage II patients sug-
gests that CMS subtyping may be of added value to
identify patients that have a high-risk, lymph node nega-
tive colon cancer. This effect might partly be explained
by stage migration, due to under-staging as a result of
low number of assessed lymph nodes; i.e. high-risk stage
II tumors contain unrecognized stage III tumors. An-
other possible explanation for the marked difference in
DFS within the CMS4 population is that these tumors
behave more like the early-dissemination model [3, 14],
instead of the classical linear-progression model in CRC.
In agreement, the existence of early disseminating can-
cer cells which evolve independently at the metastatic
site has been demonstrated in breast cancer [15]. There-
fore CMS4 tumors may benefit from treatment with
chemotherapy at an apparently early stage of progression
(stage II).
Several clinical studies found that patients with syn-
chronous and metachronous liver metastases had a
similar overall survival upon diagnosis of metastatic
disease [16–18]. This supports our hypothesis that
tumor biology is installed at an early moment in
tumor development and that this, rather than the
progression over time, is the main determinant for
prognosis in these patients. Also, determining the
CMS may not only be helpful to identify high-risk
stage II patients, but may also be used to select pa-
tients for specific treatments. Patients with an MSI
tumor (mostly CMS1) are known to have very limited
benefit from chemotherapy [19, 20]. However, these
patients may very well benefit from immunotherapy
or the addition of Bevacizumab instead of Cetuximab
to chemotherapy in metastasized CRC [21, 22]. For
epithelial-like tumors (CMS2/3) there is a predictive
value for anti-EGFR therapy [7, 23]. Patients with a
CMS2 tumor were shown to be responsive to
Oxaliplatin-containing chemotherapy while mesenchy-
mal tumors (CMS4) seemed refractory to 5FU-based
chemotherapy. These results suggest that the CMS
taxonomy may also be used to select patients for con-
ventional chemotherapy [24, 25]. Future prospective
studies should be conducted to confirm these hints
on CMS-specific drug sensitivity, as these findings
originate from retrospective studies.
The current study has several limitations. First, the
survival analysis in the subset of stage II colon cancer
may be subject to selection bias. Patients with high-risk
stage II colon cancer were excluded from the current
analysis when they did receive adjuvant chemotherapy.
However, on estimate only 10–15% of these patients ac-
tually receive adjuvant chemotherapy, and patients with
a T4 tumors and inadequate lymph node assessment
(both high-risk factors) were present in the aggregated
cohorts. Second, the additive value of the CMS for high-
risk stage II patients should be validated in larger series
given the relatively small number of patients in the high-
risk stage II cohort.
Conclusions
In conclusion, this study provides evidence to support
the hypothesis that tumor stage and the corresponding
prognosis are at least partly driven by tumor biology ra-
ther than the time of diagnosis. The CMS classification
system has the potential to be a major contributor to
clinical decision making. Therefore, future efforts should
focus on further substantiating these findings and the
development of a clinically applicable CMS test.
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